A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

被引：0
|
作者：
Di Giacomo, Anna Maria
Annesi, Diego
Ascierto, Paolo Antonio
Calabro, Luana
Chiarion-Sileni, Vanna
Danielli, Riccardo
Del Vecchio, Michele
Ferraresi, Virginia
Ferrucci, Pier Francesco
Fonsatti, Ester
Guida, Michele
Giannarelli, Diana
Guidoboni, Massimo
Mandala, Mario
Quaglino, Pietro
Queirolo, Paola
Maccalli, Cristina
Parmiani, Giorgio
Maio, Michele
机构：
[1] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy
[2] Univ Hosp Siena, Siena, Italy
[3] Ist Nazl Tumori IRCCS, Naples, Italy
[4] Veneto Oncol Inst, Padua, Italy
[5] Azienda Osped Senese, Siena, Italy
[6] Ist Nazl Tumori, I-20133 Milan, Italy
[7] Regina Elena Inst Canc Res, Rome, Italy
[8] European Inst Oncol, Milan, Italy
[9] Ist Oncol, Bari, BA, Italy
[10] IRCCS IRST, Immunotherapy & Somat Cell Therapy Lab, Meldola, Italy
[11] Papa Giovanni XIII Hosp, Bergamo, Italy
[12] Univ Turin, Dermatol Clin, Dept Med Sci, Turin, Italy
[13] Natl Inst Canc Res, Genoa, Italy
[14] Italian Network Tumor Biotherapy Lab, Siena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9090
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings
    Reddy, Sangeetha M.
    Amaria, Rodabe N.
    Spencer, Christine N.
    Tetzlaff, Michael
    Reuben, Alexandre
    Andrews, Miles
    Wang, Linghua
    Woodman, Scott
    Zhu, Haifeng
    Blando, Jorge
    Vence, Luis
    Zhang, Shaojun
    Jiang, Hong
    Gopalakrishnan, Vancheswaran
    Hudgens, Courtney
    Wani, Khalida
    Tawbi, Hussein
    Diab, Adi
    Glitza, Isabella
    Patel, Sapna
    Hwu, Wen-Jen
    Wong, Michael
    Hwu, Patrick
    Cormier, Janice
    Lucci, Anthony
    Royal, Richard
    Lee, Jeffrey E.
    Simpson, Lauren
    Burton, Elizabeth M.
    Gershenwald, Jeffrey E.
    Ross, Merrick
    Allison, James
    Sharma, Padmanee
    Davies, Michael
    Wargo, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [32] A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST).
    Singh, Arun S.
    Chmielowski, Bartosz
    Hecht, J. Randolph
    Rosen, Lee S.
    Wang, Xiaoyan
    Brackert, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
    Di Giacomo, Anna Maria
    Chiarion-Sileni, Vanna
    Del Vecchio, Michele
    Ferrucci, Pier Francesco
    Guida, Michele
    Quaglino, Pietro
    Guidoboni, Massimo
    Marchetti, Paolo
    Cutaia, Ornella
    Amato, Giovanni
    Covre, Alessia
    Camerini, Roberto
    Calabro, Luana
    Valente, Monica
    Giannarelli, Diana
    Mandala, Mario
    Maio, Michele
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4737 - 4745
  • [34] Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
    Di Giacomo, A. M.
    Ascierto, P. A.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Simeone, E.
    Guidoboni, M.
    Maurichi, A.
    Orgiano, L.
    Spadola, G.
    Del Vecchio, M.
    Danielli, R.
    Calabro, L.
    Annesi, D.
    Giannarelli, D.
    Maccalli, C.
    Fonsatti, E.
    Parmiani, G.
    Maio, M.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 798 - 803
  • [35] Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)
    Robert, Caroline
    Dutriaux, Caroline
    Oppong, Felix Boakye
    Kicinski, Michal
    Routier, Emilie
    Neidhardt, Eve-Marie
    Durando, Xavier
    Baroudjian, Barouyr
    Saiag, Philippe
    Gaudy-Marqueste, Caroline
    Ascierto, Paolo Antonio
    Arance, Ana Maria
    Russillo, Michelangelo
    Perrot, Jean-Luc
    Govaerts, Anne-sophie
    Buhrer, Emanuel
    Schilling, Bastian
    Mandala, Mario
    Lorigan, Paul
    van Akkooi, Alexander Christopher Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9503 - LBA9503
  • [36] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
    Kiyohara, Y.
    Takenouchi, T.
    Uhara, H.
    Koga, H.
    Uchi, H.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)
    Duttagupta, Sreya
    Messaoudene, Meriem
    Jamal, Rahima
    Mihalcioiu, Catalin
    Belanger, Karl
    Lenehan, John
    Belkaid, Wiam
    Parvathy, Seema Nair
    Maillou, Jade
    Hu, Yongjia
    Ponce, Mayra
    Hakozaki, Taiki
    Salazar, Eder Mendez
    Silverman, Michael
    Vareki, Saman Maleki
    Elkrief, Arielle
    Routy, Bertrand
    CANCER RESEARCH, 2024, 84 (07)
  • [38] Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.
    Di Giacomo, Anna Maria
    Covre, Alessia
    Finotello, Francesca
    Rieder, Dietmar
    Sigalotti, Luca
    Giannarelli, Diana
    Petitprez, Florent
    Lacroix, Laetitia
    Cutaia, Ornella
    Fazio, Carolina
    Coral, Sandra
    Anichini, Andrea
    Bock, Christoph
    Lowder, James N.
    Azab, Mohammad
    Fridman, Wolf-Herman
    Sautes-Fridman, Catherine
    Trajanoski, Zlatko
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
    Chesney, Jason
    Puzanov, Igor
    Collichio, Frances
    Singh, Parminder
    Milhem, Mohammed M.
    Glaspy, John
    Hamid, Omid
    Ross, Merrick
    Friedlander, Philip
    Garbe, Claus
    Logan, Theodore F.
    Hauschild, Axel
    Lebbe, Celeste
    Chen, Lisa
    Kim, Jenny J.
    Gansert, Jennifer
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1658 - +
  • [40] CLINICAL OUTCOMES OF METASTATIC MELANOMA PATIENTS WITH LIVER METASTASES TREATED WITH ANTI-PD-1 MONOTHERAPY VERSUS COMBINATION IPILIMUMAB/NIVOLUMAB
    Ma, Vincent
    Griffith, Kent
    Waninger, Jessica
    Daignault-Newton, Stephanie
    Fecher, Leslie
    Lao, Ajjai Alva Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A143 - A144
12345